Brief Behavioral Therapy for Refractory Insomnia in Residual Depression: An Assessor-Blind, Randomized Controlled Trial

Norio Watanabe, MD, PhD; Toshi A. Furukawa, MD, PhD; Shinji Shimodera, MD, PhD; Ippei Morokuma, MD; Fujika Katsuki, RN, PhD; Hirokazu Fujita, MD, PhD; Megumi Sasaki, PhD; Chihiro Kawamura, BA; and Michael L. Perlis, PhD

ABSTRACT

Objective: Insomnia often persists despite pharmacotherapy in depression and represents an obstacle to its full remission. This study aimed to investigate the added value of brief behavioral therapy for insomnia over treatment as usual (TAU) for residual depression and refractory insomnia.

Method: Thirty-seven outpatients (mean age of 50.5 years) were randomly assigned to TAU alone or TAU plus brief behavioral therapy for insomnia, consisting of 4 weekly 1-hour individual sessions. The Insomnia Severity Index (ISI) scores (primary outcome), sleep parameters, and GRID-Hamilton Depression Rating Scale (GRID-HAMD) scores were assessed by blind raters and remission rates for both insomnia and depression were collected at 4- and 8-week follow-ups. The patients were recruited from February 18, 2008, to April 9, 2009.

Results: Brief behavioral therapy for insomnia plus TAU resulted in significantly lower ISI scores than TAU alone at 8 weeks (P < .0005). The sleep efficiency for the combination was also significantly better than that for TAU alone (P = .015). Significant differences were observed in favor of the combination group on both the total GRID-HAMD scores (P = .013) and the GRID-HAMD scores after removing the 3 sleep items (P = .008). The combination treatment produced higher rates of remission than TAU alone, both in terms of insomnia (50% vs 0%), with a number needed to treat (NNT) of 2 (95% CI, 1–4), and in terms of depression (50% vs 6%), with an NNT of 2 (95% CI, 1–5).

Conclusions: In patients with residual depression and treatment refractory insomnia, adding brief behavioral therapy for insomnia to usual clinical care produced statistically significant and clinically substantive added benefits.

Trial Registration: clinicaltrials.gov Identifier: NCT00610259


Corresponding author: Norio Watanabe, MD, PhD, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601 Japan (norio@med.nagoya-cu.ac.jp).

Insomnia occurs in 80%–90% of patients with untreated major depression.1,2 Insomnia concurrent with depression not only is a major source of subjective distress but also most likely interacts with other depressive symptoms so as to confer greater illness severity.3–6 Further, insomnia not only is the most likely symptom to persist following treatment7,8 but also may constitute an obstacle for patients to achieve full remission and recovery,9–10 and its persistence may serve as a risk factor for relapse.11 Thus, insomnia is no longer considered a simple accompanying symptom of depression but is regarded as a comorbid disorder. Given this shift in perspective, it follows that it may be useful to provide targeted treatment for the insomnia that occurs in the context of depression.

To date, there have been two trials that evaluate how insomnia treatment can be combined with traditional antidepressant therapies: one with pharmacotherapy12 and one with cognitive-behavioral therapy for insomnia.13 A multicenter randomized controlled trial (RCT)14 has found that adding a hypnotic to antidepressant treatment led to improvement in both sleep and depression. However, 50% and 58% of patients treated with the combination therapy were still nonremitters in terms of insomnia and depression, respectively, at the end of the trial. The cognitive-behavioral therapy for insomnia is based on a multicomponent approach that includes several modules,14 including sleep hygiene education, sleep restriction, and stimulus control as first-line interventions and cognitive therapy, relaxation training, and sleep compression as adjunctive ones.15 For primary insomnia, the efficacy of cognitive-behavioral therapy for insomnia has been well established.16,17 For comorbid insomnia in depression, there has been only one trial13 of cognitive-behavioral therapy for insomnia, which investigated the efficacy of adding 7-session individual cognitive-behavioral therapy for insomnia to antidepressant pharmacotherapy in acute phase treatment. The combination therapy achieved remission rates of 50% for insomnia and 62% for depression.

Neither of these two trials, however, included patients with depression and insomnia refractory to adequate pharmacotherapy.12,13 Thus, effective treatment is needed for insomnia in depression, especially one that persists after adequate pharmacotherapy. In the present study, we aimed to develop a brief behavioral therapy for insomnia by focusing on core components of cognitive-behavioral therapy for insomnia and to conduct an RCT to examine its effectiveness when added to treatment as usual (TAU), in comparison with TAU alone, for residual depression with refractory insomnia.

METHOD

Participants

Patients were recruited from February 18, 2008, to April 9, 2009, at 3 psychiatric outpatient departments in Japan.

We aimed to include patients with currently partially remitted, mild, or moderate depression, who presented with significant insomnia, despite...
adequate pharmacologic treatment. Inclusion criteria were outpatients who (1) had DSM-IV major depressive disorder, as diagnosed by the Structured Clinical Interview for DSM-IV (SCID)\(^2\); (2) were aged between 20 and 70 years; (3) for the index episode, had already been on maximum doses of 2 types of antidepressants for at least 4 weeks each (depression is usually regarded resistant or refractory when at least 2 trials with antidepressants from different pharmacologic classes fail to produce a significant clinical improvement\(^1\)); (4) had a score of 2 on at least 1 of the 3 sleep items of the GRID-Hamilton Depression Rating Scale (GRID-HAMD),\(^20\) which has explicit anchor points for each assessment item and has excellent interrater validity among even untrained raters\(^21\); (5) had a score of 8 or more on the Insomnia Severity Index (ISI),\(^14,22,23\) which is now considered a standard measure of the global severity of insomnia and is used in many studies\(^12,13,24\) (the total score of 8–14 indicates subthreshold insomnia and 15–28, clinical insomnia); and (6) had a score between 8 and 23 on the 17-item GRID-HAMD, representing current subthreshold to moderate depression.\(^25\)

Exclusion criteria were (1) mental or physical status requiring hospitalization; (2) serious suicidal risk; (3) having had or currently receiving any structured psychotherapy; (4) current diagnosis of primary anxiety or personality disorder, substance abuse or dependence, or psychosis; a history of schizophrenia or bipolar disorder; or significant medical problems; (5) duration of depression shorter than 2 months; (6) insomnia possibly being due to sleep apnea or periodic limb movements during sleep. Possible sleep apnea was assessed by using the Berlin Questionnaire\(^26\); (7) engaging in work involving night-shift; and (8) patients currently taking methylphenidate or modafinil. Any other psychotropic medications, including antidepressants and hypnotics, and prescriptions for medical conditions were allowed.

**Study Design**

Assessor-blind, individually randomized, parallel-group trial design was employed. An independent statistician generated the random allocation sequences by the computer, using variable blocks and stratified by the severity of depression (the total GRID-HAMD score of 14 or more, or less than 14) and by study sites. Allocation sequences were kept centrally, and the allocation was provided by facsimile to each site upon notification of a patient's enrollment.

Participants were randomized to brief behavioral therapy for insomnia plus TAU or TAU alone. Neither patients nor physicians of TAU were blind to allocation. However, all patients were requested not to reveal their allocated treatment to the assessors for the GRID-HAMD. After each assessment, an assessor guessed which group the patient had been assigned to, making it possible to examine if the blinding was successful.

**Assessment Measures**

Patients were assessed at baseline and at 4 and 8 weeks. Patients who dropped out of the intervention were asked to complete the assessments.

The primary outcome was the total ISI score at 8 weeks. The secondary outcomes were the total 17-item GRID-HAMD score and the 14-item GRID-HAMD score (excluding the 3 sleep items) at 4 and 8 weeks. The interrater reliability of the GRID-HAMD was calculated by audiotaping assessment sessions and having another rater assess the recordings independently. The secondary outcomes for sleep included the ISI score at 4 weeks and the Pittsburgh Sleep Quality Index (PSQI)\(^27,28\) score, the sum of the 3 sleep items on the GRID-HAMD, and sleep parameters, such as sleep efficiency, total sleep time, sleep onset latency, time wake after sleep onset, collected through the PSQI, at 4 and 8 weeks. These sleep parameters are thought to enable quantification of the presenting sleep complaint.\(^14\) Sleep diaries were employed only in the intervention arm as one of the active treatment components and thus not used to collect sleep parameters.

Dichotomous outcomes were also considered. Patients were considered as remitters for insomnia if their ISI score was less than 8\(^24\) and as remitters for depression if their 17-item GRID-HAMD score was less than 8.\(^25\) If any unfavorable event (ie, suicidal attempt, death, hospital admission) occurred during the study period, it was reported. All antidepressant and hypnotic dosages were converted into defined daily dose\(^29\) and summed.

**Sample Size**

Sample size was based on a power analysis conducted for the ISI scores. Effect sizes were estimated from previous studies on insomnia in depression (a Cohen \(d\) of 0.95 on the ISI total scores at posttreatment between the combined escitalopram plus cognitive-behavioral therapy for insomnia arm and the escitalopram plus pseudodesensitization arm\(^30\) and a Cohen \(d\) of 1.81 in sleep efficiency pre– to post–cognitive-behavioral therapy for insomnia\(^31\)) and from brief behavioral therapy for insomnia pilot data from our group acquired prior to this study (the mean change in the ISI scores pretreatment to posttreatment was 6.75 in 4 patients). The mean ± SD change in the ISI scores pretreatment to posttreatment was estimated to be 6 ± 3 for the brief behavioral therapy for insomnia plus TAU group and 2 ± 3 for the TAU group. With 0.9 power to detect a significant difference at \(P = .05\) (2-sided), it was calculated that 12 patients would be required for each arm. Thus, allowing for a 30% dropout rate, 18 participants would need to be recruited per group.

**Trial Interventions**

The treatment regimen for the present study was developed and highly structured based on a published treatment manual for cognitive-behavioral therapy for insomnia\(^15\) and was provided to therapists as a written manual. The program consisted of 4 weekly individual sessions, each lasting approximately 50 minutes (Table 1). The number of the sessions, while fewer than traditional cognitive-behavioral therapy for insomnia\(^15\) and those in the previous studies,\(^13,24\) is nevertheless in keeping with (1) the finding that 4 sessions may constitute the optimal dose for cognitive-behavioral therapy for insomnia\(^32\) and (2) recent studies showing the
Table 1. Overview of Principles in Treatment Sessions in the Brief Behavioral Therapy for Insomnia Condition

<table>
<thead>
<tr>
<th>Session</th>
<th>Module</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Sleep diary</td>
<td>The aim is to increase patients’ awareness of their own maladaptive sleep habits, thus paving the way for the correction of these habits. In addition, the sleep diary allows both the patient and the clinician to gather the data needed to measure and guide treatment.</td>
</tr>
<tr>
<td>2</td>
<td>Sleep hygiene education</td>
<td>The patient learns about the impact of lifestyle habits, such as exercise; diet and alcohol use; and the influence of environmental factors, such as light, noise, and temperature in the bedroom.</td>
</tr>
<tr>
<td>2</td>
<td>Introduction of the behavioral model of insomnia</td>
<td>Discussion of predisposing, precipitating, and perpetuating factors of patient’s insomnia. Presenting the perspective to the patient so that he or she understands why the interventions may benefit, which is thus likely to enhance adherence.</td>
</tr>
<tr>
<td>2</td>
<td>Sleep restriction</td>
<td>Involves a strict schedule of bed times and rising times, restricting patients’ allowed time in bed to the actual sleeping time according to the patients’ sleep diary; the aim is to increase homeostatic sleep drive through partial sleep deprivation.</td>
</tr>
<tr>
<td>2</td>
<td>Stimulus control</td>
<td>The aim is to break associations between the sleep environment and wakefulness by teaching the participant not to engage in bedroom activities incompatible with sleep and to stay in bed only when asleep or sleepy.</td>
</tr>
<tr>
<td>3</td>
<td>Sleep titration</td>
<td>The objective is to assess treatment gains and compliance and to make adjustments to the patient’s sleep schedule according to a weekly average sleep efficiency.</td>
</tr>
<tr>
<td>4</td>
<td>Sleep titration</td>
<td>Same as above.</td>
</tr>
<tr>
<td>4</td>
<td>Relapse prevention</td>
<td>Involves a review of how insomnia started and how it maintained over time. Afterward, discussion about the approach to maintaining clinical gains in the long run and what to do when insomnia recurs.</td>
</tr>
</tbody>
</table>

Figure 1. Participant Flow Diagram

Abbreviation: TAU = treatment as usual.
effectiveness of brief behavioral therapy for primary insomnia. Patients allocated to brief behavioral therapy for insomnia were asked to self-administer these skills after the termination of the intervention sessions at 4 weeks until the final assessment at 8 weeks.

Therapists for brief behavioral therapy for insomnia were 5 psychiatrists and a psychiatric nurse. All therapists had 3 or more years of clinical experience in psychiatry; however, all but one psychiatrist had not received formal cognitive-behavioral therapy training. They participated in a 2-day intensive training course on brief behavioral therapy for insomnia before the study commencement and received ongoing supervision monthly thereafter.

Treatment as usual involved having patients meet with their physician (psychiatrist) biweekly during which time they discussed their depression symptoms and obtained medication. Each session typically lasted 10 minutes. Physicians empathetically listened to patients’ distress during the sessions, but changing types and doses of medication was not allowed in the first 4 weeks of the study unless rapid exacerbation of depression occurred. Physicians were allowed to discuss sleep hygiene as defined in the handout prepared for the study, but they were not permitted to discuss sleep restriction and stimulus control for insomnia.

For the assessment of integrity of both brief behavioral therapy for insomnia and TAU sessions, all sessions were audiotaped and 20% of each condition were randomly selected and evaluated by 2 independent researchers for adherence to the treatment manual or to the TAU materials.

Data Management and Analysis

Descriptive and inferential statistics were computed using SPSS for Windows 16.0. All analyses were based on the intent-to-treat model. When there were no missing data, analysis of covariance was used to test group effects while controlling for the baseline scores. When missing data were observed, linear mixed models were used for continuous variables, and dropouts were assumed nonresponders for dichotomous variables. A P value < .05 was set to test the null hypothesis. For dichotomous variables, risk ratios and their 95% confidence intervals (CIs) were calculated. A number needed to treat (NNT) was calculated when a 95% CI of risk ratio did not include 1.0.

No statistical tests were planned to detect a difference at baseline between the 2 arms because we aimed to avoid multiple tests, and the decision to adjust for baseline possible confounds.

The protocol was approved by the ethics committees of all the recruiting centers. Written informed consent was obtained from all participants. The study is registered at clinicaltrials.gov (identifier: NCT00610259).

RESULTS

Enrollment and Baseline Characteristics of the Participants

Eighty-nine patients were screened and 37 patients satisfied the eligibility criteria, with 20 participants randomly assigned to receive the brief behavioral therapy for insomnia plus TAU therapy and 17 to the TAU therapy alone (Figure 1). Table 2 summarizes the sociodemographic and clinical characteristics of the Participants.
Attrition and Study Integrity

**Attrition.** Two participants did not complete the brief behavioral therapy for insomnia plus TAU condition, and 1 subject did not complete the TAU condition. In the brief behavioral therapy for insomnia plus TAU group, 1 patient discontinued brief behavioral therapy for insomnia after reporting that it was too difficult to comply with the prescribed sleep schedule. Beyond this reason, 1 subject in the brief behavioral therapy for insomnia plus TAU condition and 1 subject in the TAU group were admitted to hospital due to exacerbation of depression. All 3 participants nevertheless completed all the study assessments (Figure 1).

**Medication.** Antidepressant dosage was changed for 2 participants each in the 2 groups. Hypnotic dosage was changed for 2 participants in the combination group and for none of the participants in the TAU alone group. No between-group differences in defined daily doses of either drug were found for either class of medications (Table 3).

**Treatment integrity.** Sixteen randomly selected brief behavioral therapy for insomnia sessions were checked for adherence. Overall, 78.4% of the quality checkpoints had been fulfilled by the therapists. With regard to TAU, the researchers checking for adherence suspected that 2 of 30 sessions (6.7%) went beyond the sleep hygiene handout and used some techniques included in brief behavioral therapy for insomnia.

**Assessment integrity.** Nine assessors were employed for administering the GRID-HAMD. Twenty randomly selected recorded assessments were used to examine interrater reliability. Single-measure intraclass correlation coefficients between the 2 raters were 0.92 (95% CI, 0.81–0.97).

### Integrity of the blind assessors
κ Values for agreement between the actual allocation and the allocation guessed by a blind assessor at each assessment were 0.41 (95% CI, 0.13–0.69) at 8 weeks and 0.15 (95% CI, 0.00–0.45) at 4 weeks. This indicated that the blinding of the assessors was satisfactory.

### Insomnia Severity
Relative to TAU alone, treatment with combined brief behavioral therapy for insomnia and TAU therapy resulted in significantly lower ISI total scores at 8 weeks ($P < .0005$), with a mean (SE) score of 9.2 (1.1) in the combination and 15.9 (1.2) in the TAU alone, after adjusting for the baseline scores (Table 3). In a sensitivity analysis adjusting for other possibly clinical confounds at baseline, the ISI score at 8 weeks was still significantly in favor of the combination therapy ($P = .036$, data available upon request).

Significant superiority in favor of the combination group was also observed in the adjusted ISI score at 4 weeks ($P = .01$). Total PSQI scores and the sleep efficiency for the combined brief behavioral therapy for insomnia plus TAU group were significantly better than those for the TAU alone at both 8 and 4 weeks (Table 3).

### Depression Severity
For the total 17-item GRID-HAMD scores, significant differences were observed in favor of the combined brief behavioral therapy for insomnia plus TAU group both at 8 weeks ($P = .013$) and at 4 weeks ($P = .004$) (Table 3, Figure 2).

After removing the 3 sleep items, significant differences were observed in favor of the combination therapy group both at 8 weeks ($P = .008$) and at 4 weeks ($P = .005$) (Table 3).

### Remission of Insomnia and Depression
At 8 weeks, 10 participants (50.0%) in the combination group and 0 (0.0%) in the TAU alone group achieved remission in terms of insomnia, resulting in an NNT of 2 (95%...
DISCUSSION

This study represents the first randomized trial examining the use of psychotherapy for insomnia in conjunction with usual care in the treatment of residual depression and refractory insomnia despite adequate pharmacotherapy. For the primary outcome of insomnia, adding brief behavioral therapy for insomnia to TAU produced significantly greater reduction in insomnia than TAU alone. Remission in insomnia was achieved by 50% of patients treated with the combined therapy, while none of those treated with TAU alone did so (NNT = 2). Moreover, in terms of depression, greater improvement in the severity of depression was observed for patients treated with the combined therapy in comparison with TAU alone, even after removing the 3 sleep items. At 8 weeks, remission from refractory major depression was achieved among 50% of those treated with added behavior therapy, while it was achieved in only 6% of those treated with TAU alone (NNT = 2).

Manber and colleagues' recent trial of adding cognitive-behavioral therapy for insomnia to escitalopram in the acute phase treatment of major depression may suggest that cognitive-behavioral therapy for insomnia can be employed as part of the first-line treatment. However, availability of cognitive-behavioral therapy is universally limited for many reasons, including shortage of trained clinicians and associated costs. In practice, combined hypnotic and
Brief Behavioral Therapy for Insomnia in Depression

antidepressant therapy might be broadly selected as the first-line treatment rather than combined psychotherapy plus antidepressant treatment.12

On the other hand, our findings suggest that residual depression comorbid with insomnia may be effectively targeted by adding psychotherapy for insomnia that is less intensive than the standard cognitive-behavioral therapy for insomnia, that can be administered by less experienced clinicians, and that may therefore be feasible in routine clinical settings. The observed effect size (Cohen’s d) for the 17-item GRID-HAMD score was 1.01 (95% CI, 0.30–1.67) at 8 weeks. This figure is appreciably greater than that of 0.32 (95% CI, 0.11–0.53), recently reported in the meta-analysis of combining full package cognitive-behavioral therapy for depression with pharmacotherapy over pharmacotherapy alone.39 Reserving brief behavioral therapy for insomnia for the patient population that exhibits greater morbidity, instead of administering full-package cognitive-behavioral therapy for depression or cognitive-behavioral therapy for insomnia as a part of the first-line treatment, may have the apparent practical advantage of matching the limited supply of knowledgeable practitioners to those most in need.

Although the present findings are very promising, the study is not without some methodological limitations. First, no polysomnographic data were collected in the present study. We decided not to use polysomnography for the following reasons: (1) the patients had been visiting our outpatient clinics regularly, and a validated screening questionnaire for sleep apnea26 was administered to all the patients, thus sleep apnea and periodic limb movement syndromes had already been screened out through consultations; and (2) in most general outpatient settings, especially for primary care clinics, routine use of polysomnography is not feasible. Considering the subjective nature of insomnia, our decision not to use polysomnography does not undermine the importance of our findings. In addition, sleep parameters were collected through the PSQI, which has not been validated for this purpose. Although sleep diary was not used to collect these data because it was employed only in the intervention arm as an active treatment component, this issue should be listed among the limitations. Second, the sample sizes were relatively small and concerns about the generalizability of the results may be raised, although the sizes were derived from our power calculation. In addition, the present study evaluated the patients up to 8 weeks only, and the long-term consequences of the combination treatment were unclear. Further replication study with a larger sample and long-term follow-ups is needed to evaluate these outcomes with more confidence. Third, we could not answer whether brief behavioral therapy for insomnia itself or careful watching for patients resulted in improvement in insomnia and in depression. Although an attention-placebo arm, such as relaxation or a quasi desensitization, was employed in previous studies on psychotherapy for insomnia,13,40 we aimed to conduct the study to examine the effectiveness of adding psychotherapy to usual clinical care, but not to examine the efficacy of brief behavioral therapy for insomnia itself. Fourth, because the present study was conducted in Japan, several differences possibly influencing the results may exist between our settings and those in other countries in terms of characteristics of the enrolled patients and in health care systems. Several previous studies have reported that there may be certain differences between Western culture and others that need to be considered in the application of cognitive-behavioral therapy, such as patient’s knowledge and beliefs about health and therapy41 and insight into symptoms.42 Replication studies might be needed before application of our results to patients in countries with different health care systems.

However, strengths of our study include our enthusiastic follow-ups of the patients. Even after patients were admitted to the hospital, blind assessors were sent. We, therefore, have no missing data and our results are robust. Another major strength of our study is its focus on the “effectiveness” design, as evidenced by the broad eligibility criteria for enrollment, use of less skilled therapists, preparation of a detailed manual, and shortening the treatment procedure to 4 sessions. All of these factors should contribute to the greater applicability and feasibility of our findings.

In conclusion, the results of our study suggest that adding brief behavioral therapy for insomnia to TAU is a promising treatment option for many patients with residual depression and refractory insomnia. Clinicians seeing depressed patients with persistent insomnia may consider adding brief behavioral therapy for insomnia to their usual clinical care as the second-line treatment for those who do not respond to adequate pharmacotherapy. Replication studies with a larger sample and long-term follow-ups in a different cultural setting may be needed to confirm the findings of the study with more confidence.

Author affiliations: Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences (Drs Watanabe and Furukawa); Department of Psychiatric and Mental Health Nursing, Nagoya City University School of Nursing (Dr Katsuki), Nagoya; Department of Neuropsychiatry, Kochi Medical School (Drs Shimodera, Morokuma, and Fujita, and Ms Kawamura), Kochi; Center for Education and Research on the Science of Preventive Education, Naruto University of Education, Tokushima (Dr Sasaki), Japan; and Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, Philadelphia (Dr Perlis).

Potential conflicts of interest: Dr Watanabe has received research funds from the Japanese Ministry of Education, Science, and Technology; and has received speaking fees and research funds from Asahi Kasei, Dai-Nippon Sumitomo, GlaxoSmithKline, Pfizer, and Schering-Plough. Dr Furukawa has received research funds and speaking fees from Astellas, Dai-Nippon Sumitomo, Eli Lilly, GlaxoSmithKline, Jansen, Meiji, Otsuka, Pfizer, Schering-Plough, Yoshitomi, and the Japanese Ministry of Education, Science, and Technology; has served on research advisory boards for Meiji and Mochida; and is currently serving on a research advisory board for Sekisui Chemicals and Takeda Science Foundation. Dr Shimodera has received research fees from Asahi Kasei, Dai-Nippon Sumitomo, GlaxoSmithKline, Astellas, Eli Lilly, Jansen, Meiji, Otsuka, Pfizer, Schering-Plough, Yoshitomi, and the Japanese Ministry of Education, Science, and Technology; has served on research advisory boards for Sekisui Chemicals. Dr Sasaki has received research funds from the Japanese Ministry of Education, Culture, Sports, Science and Technology. Dr Perlis is an employee of the University of Pennsylvania and has received research funds, speaking fees and consulting fees from Cephalon, Sanofi-Aventis, Vanda, and Internet Didactic Services. Drs Morokuma and Fujita and Ms Kawamura report no conflicts of interest.

Funding/support: This study was funded by a Grant-in-Aid for Scientific Research (No. 19230201) from the Ministry of Health, Labour and Welfare, Japan.
Role of sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the article.

Disclaimer: The contents of this article are solely the responsibility of the authors.

Previous presentation: A preliminary analysis of this work was presented in symposium at the 9th Annual Meeting of the Japanese Association of Cognitive Therapy; October 11–13, 2009; Chiba, Japan; and in New Research Poster Session at the 163rd Annual Meeting of the American Psychiatric Association; May 22–26, 2010; New Orleans, Louisiana.

Acknowledgments: The authors thank all the assessors and the therapists (Nao Shiraishi, MD; Yoshie Murata, MSc; Jun Mayumi, MD; Mako Morikawa, MD; Yumi Nakano, MD, PhD, at Nagoya City University Graduate School of Medical Sciences, and Ryosuke Fujito, MD, at Kochi Medical School) and the administrative staff (Kozue Maki at Nagoya City University Graduate School of Medical Sciences) for their contribution to this study. The authors also thank Mitsuhiro Yamada, MD, PhD; Naohiro Yonemoto, MSc; and Masatoshi Inagaki, MD, PhD, at National Center of Neurology and Psychiatry, Japan, for their advice regarding the design and statistical issues, and Izuru Miyoshi, MD, PhD, at National Center of Neurology and Psychiatry, for providing the central allocation. None of the acknowledged individuals report any financial or other conflicts of interest relative to the subject of the article.

REFERENCES